Vascular Biology |
From Institut National de la Santé et de la Recherche Médicale (INSERM) U 141, IFR6 Circulation Lariboisière, Université Paris VII, Paris, France.
Correspondence to D. Henrion, PhD, INSERM U 141, Hopital Lariboisiere, 41 Bd de la Chapelle, 75475 Paris, cedex 10, France. E-mail daniel.henrion{at}inserm.lrb.ap-hop-paris.fr
| Abstract |
|---|
|
|
|---|
Key Words: protein kinase C stretch extracellular signalrelated kinase mitogen-activated protein kinase rabbits
| Introduction |
|---|
|
|
|---|
However, there is no information concerning the activation of ERK1/2 in blood vessels developing myogenic tone. The rabbit facial vein (RFV) develops a myogenic tone similar to that observed in resistance arteries.3 17 Furthermore, myogenic tone is abolished in the RFV that is exposed to low temperature (33°C). Therefore, we used this experimental model to test the effect of vascular wall stretch on ERK1/2 activity in the presence (39°C) or the absence (33°C) of myogenic tone and to determine whether ERK1/2 activation is involved or affected buy the development of myogenic tone.11 18
| Methods |
|---|
|
|
|---|
Experimental Protocol
ERK1/2 activity was determined as previously
described,15 and RFV segments were submitted to one of the
following protocols. Each sample of vein was divided in 2 segments. One
of the 2 segments was used as a control vessel,16 and the
other was mounted in the myograph for force measurement. ERK1/2
activity was measured in both segments. The activity of each sample
that had been mounted in a myograph and submitted to an experimental
protocol was calculated as a percentage of the activity found in the
corresponding control unstretched segment.16
At the end of each experimental protocol, the vein segment was rapidly removed from the organ bath, frozen in liquid nitrogen, and subsequently stored at -80°C until determination of ERK1/2 activity.
In a first series of experiments, RFV segments were stretched to an optimal tension (5 mN) and allowed to stabilize for 30 minutes in the absence (33°C, n=8) or in the presence (39°C, n=11) of myogenic tone.
In a second series of experiments, RFV segments were stretched at 39°C. Veins were then exposed during 30 minutes to one of the following agents: the PKC activator phorbol dibutyrate (PDBu, 10-6 mol/L, n=11), the calcium-dependent PKC inhibitor Go-6976 (10-6 mol/L, n=9), the nonselective PKC inhibitor Ro-31-8220 (5x10-7 mol/L, n=8), or the nonselective and nonspecific kinase inhibitor staurosporine (10-7 mol/L, n=7).
In a third series of experiments, the involvement of tyrosine kinase and ERK1/2 was assessed in RFV segments with or without myogenic tone. The tyrosine kinase inhibitors genistein (10-7 mol/L, n=9, 30 minutes) and herbimycin A (5x10-7 mol/L, n=7, 30 minutes) were used separately. Specific inhibition of MAP kinase kinase activity was obtained by using PD 98059 (5x10-6 mol/L, n=6, 30 minutes).
In a fourth series of experiments, the involvement of calcium in myogenic tone and ERK1/2 activity was assessed in the presence of stretch, with or without myogenic tone. Vein segments were submitted to a calcium-free physiological salt solution containing EGTA (2 mmol/L, n=9), to nifedipine (10-6 mol/L, n=6), or to ryanodine (10-6 mol/L, n=6).
In each protocol, the pharmacological agent was left for 30 minutes in the organ bath before stretching the segment. Myogenic tone was monitored continuously from the onset of each experiment.
Tissue Extraction
Tissue extraction was performed as previously
described16 : frozen vessel segments were pulverized in
liquid nitrogen. The powders were resuspended in ice-cold lysis buffer
of the following composition: 20 mmol/L Tris-HCl (pH 7.5), 5
mmol/L EGTA, 150 mmol/L NaCl, 20 mmol/L glycerophosphate,
10 mmol/L NaF, 1 mmol/L sodium orthovanadate, 1% Triton
X-100, 0.1% Tween 20, 1 µg/mL aprotinin, 1 mmol/L
phenylmethylsulfonyl fluoride, 0.5 mmol/L
N-tosyl-L-phenylalanine chloromethyl
ketone, and 0.5 mmol/L
N
-p-tosyl-L-lysine
chloromethyl ketone at a ratio of 0.3 mL/10 mg wet weight. Vein
extracts were incubated in this buffer on ice for 15 minutes and then
centrifuged (12 000g, 15 minutes, 4°C). The
detergent-soluble supernatant fractions were retained, and protein
concentrations in samples were equalized by using a Bio-Rad protein
assay.
In-Gel ERK1/2 Assays
Kinase assays in myelin basic protein (MBP)-containing gels were
performed as described previously.16 Laemmli sample buffer
(70 µL) was added to 100 µL aliquots of vein extracts, and samples
were loaded on a 9% SDS-polyacrylamide gel containing 0.5
mg/mL MBP. After electrophoresis, SDS was removed from the gel by
washing with 3 changes at 100 mL each of 20% 2-propanol in 50
mmol/L Tris-HCl (pH 8.0) for 15 minutes and then with 100 mL of 50
mmol/L Tris-HCl (pH 8.0) containing 5 mmol/L 2-mercaptoethanol for
30 minutes at room temperature. Gels were further treated with 50 mL of
6 mol/L guanidine-HCl in 50 mmol/L Tris-HCl (pH 8.0) at room
temperature for 1 hour, followed by 5 changes of 50 mmol/L
Tris-HCl (pH 8.0) containing 0.04% Tween 20 and 5 mmol/L
2-mercaptoethanol at room temperature for 15 minutes each. Gels were
left in the same buffer at +4°C overnight. Afterward, gels were
immersed in 10 mL of 40 mmol/L HEPES (pH 8.0) containing 2
mmol/L dithiothreitol and 10 mmol/L MgCl2
for 1 hour at 25°C. Phosphorylation of MBP was
carried out by incubating the gels with 50 µCi
[
-32P]ATP at 25°C for 3 hours in 10 mL of
40 mmol/L HEPES (pH 8.0) containing 2 mmol/L dithiothreitol,
10 mmol/L MgCl2, 0.5 mmol/L EGTA, and
40 µmol/L ATP. After incubation, the gels were washed with 10%
acetic acid and 1% sodium pyrophosphate until the radioactivity of the
washing solution became negligible. The washed gels were dried and then
subjected to autoradiography.
Materials
[
-32P]ATP (6000 Ci/mmol) was obtained
from Amersham (Les Ulis). Gel electrophoresis reagents came from
Bio-Rad; staurosporine, from LC Laboratories Europe; and
Ro-31-8220 and Go-6976, from France-Biochem. The MAP kinase kinase
inhibitor (PD 98059) was purchased from New England
Biolabs. All other reagents were obtained from Sigma Chemical
Co.
Data Analysis
All experiments were performed at least 5 times, and results are
expressed as mean±SE. A 1-way ANOVA was constructed with data of
ERK1/2 activity to test the effects of time and pressure. Comparisons
were performed by use of the Tukey test. Statistical significance was
accepted for values of P<0.05.
| Results |
|---|
|
|
|---|
|
ERK1/2 activity was determined in RFV segments submitted to stretch for
30 minutes (Figure 2
). In vein
segments without stretch, the basal ERK1/2 activity was considered to
be 100%. The time course of stretch-induced activation of MAP kinase
activation was as follows: 282±52% (n=11) at 30 minutes, 268±38%
after 40 minutes (n=5), 259.4±47% after 60 minutes (n=5), 230.3±41%
(n=5) after 2.5 hours, and 169.2±23% (n=5) after 5.5 hours.
|
In the absence of myogenic tone (33°C), stretch induced an
increase in ERK1/2 activity (254±35%, n=8; P<0.05 versus
unstretched RFV) (Figure 3
), providing
evidence that ERK1/2 is not activated by myogenic tone. In RFV
segments maintained at 39°C (myogenic tone present), stretch
increased ERK1/2 activity to an extent similar to that at 33°C
(282±52%, n=11; P<0.05 versus unstretched RFV) (Figure 3
).
|
The role of PKC in stretch-induced ERK1/2 activity and myogenic tone
was assessed by using inhibitors or activators
of PKC at 39°C, in the presence of myogenic tone (Figure 4
). On the other hand, Ro-31-8220
(5x10-7 mol/L), a specific
inhibitor of all PKCs, induced a total blockade of myogenic
tone but did not affect ERK1/2 activity (264±47% versus unstretched
control veins, n=9). The selective calcium-dependent PKC
inhibitor Go-6976 (10-6 mol/L) had a
significant effect neither on myogenic tone (4.58±0.57 versus
5.7±0.59 mN in control conditions, n=8) nor on
ERK1/2 activity (225±48% versus unstretched control veins,
n=8). Only staurosporine, a nonspecific kinase
inhibitor (10-7 mol/L), abolished
both myogenic tone and ERK1/2 activity. Activation of PKC with PDBu
(10-6 mol/L) increased myogenic tone (10.7±1.8
mN, n=11; P<0.05) and ERK1/2 activation (570±129%, n=11;
P<0.05). Downregulation of PKCs with PDBu
(10-6 mol/L, 24 hours) did not significantly
affect myogenic tone (4.6±1 versus 5.7±1.8 mN in control conditions)
but partially decreased ERK1/2 activity (157±14%). These
inhibitors had the same effect on ERK1/2 activity at 33°C
as at 39°C (data not shown).
|
The role of tyrosine kinases in stretch-induced ERK1/2 activity and
myogenic tone was assessed by using 2 inhibitors (Figure 5
). Genistein
(10-7 mol/L), a broad tyrosine kinase
inhibitor, abolished ERK1/2 activity
(121.8±50.2%, n=9 stretched vessels), whereas herbimycin A
(5x10-7 mol/L), a c-src family
tyrosine kinase inhibitor, did not affect ERK1/2 activity
(276±12.3%, n=7 stretched vessels). Neither genistein nor
herbimycin A significantly affected myogenic tone. The specific MAP
kinase kinase inhibitor, PD 98059
(5x10-6 mol/L), significantly decreased ERK1/2
activity at 39°C (33.2±8.4% decrease in stretched vessels [n=6]
versus unstretched vessels) without affecting myogenic tone. Similarly,
PD 98059 decreased ERK1/2 activity at 33°C (29.4±4.6% decrease in
stretched vessels [n=6] versus unstretched vessels).
|
Both the voltage-dependent calcium channel inhibitor
nifedipine (10-6 mol/L) and
ryanodine (10-6 mol/L), which depletes calcium
stores, inhibited ERK1/2 activity (Figure 6
) (113±12.4%, n=6, and
121±7.4%, n=6, respectively) without affecting myogenic
tone (Figure 6
). On the other hand, in vessels bathed in a
0-calcium physiological salt solution+EGTA (2
mmol/L), both myogenic tone and ERK1/2 activity were abolished.
|
| Discussion |
|---|
|
|
|---|
Although myogenic tone is mainly studied in resistance arteries, it also occurs in veins.19 As pointed out by Monos,20 only recently have veins been considered "an active component of the cardiovascular system." In veins, myogenic tone is an active regulator of systemic venous capacity.19 20 21 Myogenic tone in the RFV is very similar to that in resistance arteries,1 2 3 but it is temperature sensitive.11 18 22 This unique feature was used to measure ERK1/2 activation on stimulation by stretch in the presence or in the absence of myogenic tone.
The ERK1/2 pathway is involved in a rapid transduction of growth signals and mechanical strain into regulation of gene expression and protein synthesis. Cyclic stretch in cardiac myocytes stimulates several kinases, including tyrosine kinases, ERK1/2, and PKC.23 The ERK1/2 pathway is involved in the vascular smooth cell response to contractile and proliferative stimuli. In addition, mechanical stretch leads to the activation of the ERK1/2 pathway in vivo.24
The implication of calcium in myogenic tone has been previously shown in arteries23 and veins.11 23 The degree of involvement of voltage-activated channels is dependent on the type of vessel studied. Voltage-activated channels play a major role in cerebral arteries,25 26 whereas they are only partly involved in coronary arteries27 and do not play a role in the RFV (present study). A role for PKC activation in myogenic tone has been previously suggested in studies in which myogenic tone was inhibited by pharmacological agents in arteries4 and veins. Nevertheless, in these studies, the selectivity of the PKC inhibitors was rather weak.18 Using recent and more selective PKC inhibitors, we could show that calcium-independent PKC(s) are involved in myogenic tone in the RFV. This observation is compatible with previous studies showing that myogenic tone in this vessel depends on a low increase in intracellular calcium,9 suggesting that myogenic tone might be related to a PKC-dependent sensitization of the contractile apparatus to calcium in the RFV9 and in resistance arteries.28 We have previously shown that myogenic tone in the RFV is related to a much lower ratio of calcium influx to force than other forms of tone, such as agonist- or KCl-induced tone.9 Nevertheless, further investigation might be needed to obtain more direct evidence that a sensitization of the contractile apparatus may occur when myogenic tone develops. However, myogenic tone was not sensitive to tyrosine kinase or MAP kinase kinase blockade, suggesting that its development does not require prior activation of the ERK1/2 activation pathway. Both in the presence or in the absence of myogenic tone, ERK1/2 activation by stretch was inhibited by the MAP kinase kinase inhibitor PD 98059. In addition, ERK1/2 activation was sensitive to genistein but not to herbimycin A, suggesting the absence of involvement of c-src in the process. This is at variance with previous studies in the rabbit aorta showing that pressure-induced stretch activates ERK1/2 through a PKC-independent and a c-srcdependent signaling pathway. This difference may be explained by a difference in vessel type (artery versus vein) or vessel caliber. ERK1/2 activation was also dependent on a calcium entry through voltage-operated channels and on a calcium release from the sarcoplasmic reticulum. PKC activation was not necessary for the activation of ERK1/2 by stretch. The kinetics of activation of ERK1/2 was similar in the 2 types of vessels. In swine carotid arteries, stretch-induced ERK1/2 activation25 29 is only partly dependent on calcium.28
The level of ERK1/2 activation was similar at 33°C and 39°C, and the inactivation of ERK1/2 by PD 98059, a specific MAP kinase kinase inhibitor, was total at both temperatures. Thus, we can exclude a specific effect of temperature on ERK1/2 activation.
The dissociation between force development on stretch (myogenic tone) and stretch-induced ERK1/2 activation is in agreement with recent studies that have reported a similar dissociation between wall force and ERK1/2 activation in swine carotid arteries stimulated by histamine and phorbol ester30 and in the rat aorta in response to angiotensin II.31 Thus, 2 distinct pathways were activated by stretch. One led to myogenic tone through a PKC-dependent pathway, and one led to ERK1/2 activation through a calcium-dependent and PKC-independent pathway.
Received January 7, 1999; accepted May 11, 1999.
| References |
|---|
|
|
|---|
2.
Osol G, Laher I, Cipolla M. Protein kinase C modulates
basal myogenic tone in resistance arteries from the cerebral
circulation. Circ Res.. 1991;68:359367.
3.
Narayanan J, Imig M, Roman RJ, Harder DR.
Pressurization of isolated renal arteries increases inositol
trisphosphate and diacylglycerol. Am J Physiol. 1994;266:H1840H1845.
4.
Langton PD. Calcium channel currents recorded from
isolated myocytes of rat basilar artery are stretch sensitive.
J Physiol (Lond). 1993;471:111.
5. Kulik TJ, Bialecki RA, Colucci WS, Rothmnn A, Glennon T, Underwood RH. Stretch increases inositol triphosphate and inositol tetrakisphosphate in cultured pulmonary vascular smooth muscle cells. Biochem Biophys Res Commun. 1991;180:983987.
6. Komuro I, Yazaki Y. Intracellular signaling pathways in cardiac myocytes induced by mechanical stress. Trends Cardiovasc Med. 1994;4:117121.
7. Barany K, Rokolya A, Barany M. Stretch activates myosin light chain kinase in arterial smooth muscle. Biochem Biophys Res Commun. 1990;183:164171.
8.
Knot HJ, Standen NB, Nelson MT. Ryanodine receptors
regulate arterial diameter and wall
[Ca2+] in cerebral arteries of rat via
Ca2+-dependent K+ channels.
J Physiol (Lond). 1998;508:211221.
9.
Henrion D, Laher I, Bevan JA. Intraluminal flow
increases vascular tone and
45Ca2+ influx in the rabbit
facial vein. Circ Res. 1992;71:339345.
10.
Wilson E, Mai Q, Sudhir K, Weiss R. H, Ives HE.
Mechanical strain induces growth of vascular smooth muscle cells via
autocrine action of PDGF. J Cell Biol. 1993;123:741747.
11.
Barany K, Ledvora RF, Mougios V, Barany M.
Stretch-induced myosin light chain phosphorylation and
stretch-release-induced tension development in arterial
smooth muscle. J Biol Chem. 1985;260:71267130.
12.
Shirinsky VP, Antonov AS, Birukov KG, Sobolesvky AV,
Romanov YA, Kabaeva NV, Antonova GN, Smirnov VN. Mechano-chemical
control of human endothelium orientation and size.
J Cell Biol. 1998;109:331339.
13. Masumoto N, Nakayama K, Oyabe A, Uchino M, Ishii K, Obara K, Tanabe Y. Specific attenuation of the pressure-induced contraction of rat cerebral artery by herbimycin A. Eur J Pharmacol. 1997;330:5563.[Medline] [Order article via Infotrieve]
14. Papadaki M, Eskin SG. Effects of fluid shear stress on gene regulation of vascular cells. Biotechnol Prog.. 1997;13:209221.[Medline] [Order article via Infotrieve]
15.
Lehoux S, Tedgui A. Signal transduction of mechanical
stresses in the vascular wall. Hypertension.. 1998;32:338345.
16.
Birukov KG, Lehoux S, Birukova AA, Merval R, Tkachuk
VA, Tedgui A. Increased pressure induces sustained protein kinase
Cindependent herbimycin Asensitive activation of extracellular
signalrelated kinase 1/2 in the rabbit aorta in organ culture.
Circ Res.. 1997;81:895903.
17. Winquist RJ, Bevan JA. Temperature sensitivity of tone in the rabbit facial vein: myogenic mechanism for cranial thermoregulation. Science. 1980 29;207:10011002.
18. Henrion D, Laher I. Effects of staurosporine and calphostin C, two structurally unrelated inhibitors of protein kinase C, on vascular tone. Can J Physiol Pharmacol. 1993;7:521524.
19.
Berczi V, Greene AS, Dornyei G, Csengody J, Hodi G,
Kadar A, Monos E. Venous myogenic tone: studies in human and
canine vessels. Am J Physiol.. 1992;263:H315H320.
20.
Monos E. How does the vein wall respond to pressure?
News Physiol Sci. 1993;8:124128.
21.
Koller A, Dornyei G, Kaley G. Flow-induced responses in
skeletal muscle venules: modulation by nitric oxide and
prostaglandins. Am J Physiol. 1998;275:H831H836.
22.
Dornyei G, Monos E, Kaley G, Koller A. Myogenic
responses of isolated rat skeletal muscle venules: modulation by
norepinephrine and endothelium.
Am J Physiol. 1996;271:H267H272.
23.
Laher I, van Breemen C, Bevan JA. Stretch-dependent
calcium uptake associated with myogenic tone in rabbit facial vein.
Circ Res. 1988;63:669672.
24.
Sadoshima J, Izumo S. Signal transduction
pathways of angiotensin IIinduced c-fos gene
expression in cardiac myocytes in vitro: roles of phospholipid-derived
second messengers. Circ Res. 1993;73:424438.
25.
Pyles JM, March KL, Franklin M, Mehdi K, Wilensky RL,
Adam LP. Activation of MAP kinase in vivo follows balloon overstretch
injury of porcine coronary and carotid arteries. Circ
Res. 1997;81:904910.
26. Bevan JA. Diltiazem selectively inhibits cerebrovascular extrinsic but not intrinsic myogenic tone. Circ Res. 1983;52(suppl I):I-104I-109.
27.
McCarron JG, Crichton CA, Langton PD, MacKenzie A,
Smith GL. Myogenic contraction by modulation of voltage-dependent
calcium currents in isolated rat cerebral arteries. J
Physiol (Lond).. 1997;498:371379.
28.
Davis MJ, Meininger GA, Zawieja DC.
Stretch-induced increases in intracellular calcium of isolated vascular
smooth muscle cells. Am J Physiol. 1992;263:H1292H1299.
29.
DAngelo G, Davis MJ, Meininger GA. Calcium and
mechanotransduction of the myogenic response. Am J
Physiol. 1997;273:H175H182.
30.
Franklin MT, Wang CL, Adam LP. Stretch-dependent
activation and desensitization of mitogen-activated protein
kinase in carotid arteries. Am J Physiol. 1997;273:C1819C1827.
31.
Gorenne I, Su X, Moreland RS. Inhibition of p42 and p44
MAP kinase does not alter smooth muscle contraction in swine carotid
artery. Am J Physiol. 1998;275:H131H138.
32.
Watts SW, Florian JA, Monroe KM. Dissociation of
angiotensin II-stimulated activation of
mitogen-activated protein kinase kinase from vascular
contraction. J Pharmacol Exp Ther. 1998;286:14311438.
This article has been cited by other articles:
![]() |
C. Dubroca, X. Loyer, K. Retailleau, G. Loirand, P. Pacaud, O. Feron, J.-L. Balligand, B. I. Levy, C. Heymes, and D. Henrion RhoA activation and interaction with Caveolin-1 are critical for pressure-induced myogenic tone in rat mesenteric resistance arteries Cardiovasc Res, January 1, 2007; 73(1): 190 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mercier, M. Osborne-Pellegrin, K. El Hadri, A. Kakou, C. Labat, L. Loufrani, D. Henrion, P. Challande, S. Jalkanen, B. Feve, et al. Carotid arterial stiffness, elastic fibre network and vasoreactivity in semicarbazide-sensitive amine-oxidase null mouse Cardiovasc Res, November 1, 2006; 72(2): 349 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Xiao, J. N. Buchholz, and L. Zhang Pregnancy attenuates uterine artery pressure-dependent vascular tone: role of PKC/ERK pathway Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2337 - H2343. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dubroca, D. You, B. I. Levy, L. Loufrani, and D. Henrion Involvement of RhoA/Rho Kinase Pathway in Myogenic Tone in the Rabbit Facial Vein Hypertension, May 1, 2005; 45(5): 974 - 979. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. KJAeR Role of Extracellular Matrix in Adaptation of Tendon and Skeletal Muscle to Mechanical Loading Physiol Rev, April 1, 2004; 84(2): 649 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. G. Birukov, J. R. Jacobson, A. A. Flores, S. Q. Ye, A. A. Birukova, A. D. Verin, and J. G. N. Garcia Magnitude-dependent regulation of pulmonary endothelial cell barrier function by cyclic stretch Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L785 - L797. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Spurrell, T. V. Murphy, and M. A. Hill Intraluminal pressure stimulates MAPK phosphorylation in arterioles: temporal dissociation from myogenic contractile response Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1764 - H1773. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. L. S. Brookes and S. Kaufman Myogenic responses and compliance of mesenteric and splenic vasculature in the rat Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1604 - R1610. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Massett, Z. Ungvari, A. Csiszar, G. Kaley, and A. Koller Different roles of PKC and MAP kinases in arteriolar constrictions to pressure and agonists Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2282 - H2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lagaud, N. Gaudreault, E. D. W. Moore, C. van Breemen, and I. Laher Pressure-dependent myogenic constriction of cerebral arteries occurs independently of voltage-dependent activation Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2187 - H2195. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schubert, V. U. Kalentchuk, and U. Krien Rho kinase inhibition partly weakens myogenic reactivity in rat small arteries by changing calcium sensitivity Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2288 - H2295. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Korita, N. Sagawa, H. Itoh, S. Yura, M. Yoshida, K. Kakui, M. Takemura, C. Yokoyama, T. Tanabe, and S. Fujii Cyclic Mechanical Stretch Augments Prostacyclin Production in Cultured Human Uterine Myometrial Cells from Pregnant Women: Possible Involvement of Up-Regulation of Prostacyclin Synthase Expression J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5209 - 5219. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Loufrani, Z. Li, B. I. Levy, D. Paulin, and D. Henrion Excessive Microvascular Adaptation to Changes in Blood Flow in Mice Lacking Gene Encoding for Desmin Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1579 - 1584. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wretman, A. Lionikas, U. Widegren, J. Lannergren, H. Westerblad, and J. Henriksson Effects of concentric and eccentric contractions on phosphorylation of MAPKerk1/2 and MAPKp38 in isolated rat skeletal muscle J. Physiol., August 15, 2001; 535(1): 155 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Matrougui, L. B. Tanko, L. Loufrani, D. Gorny, B. I. Levy, A. Tedgui, and D. Henrion Involvement of Rho-Kinase and the Actin Filament Network in Angiotensin II-Induced Contraction and Extracellular Signal-Regulated Kinase Activity in Intact Rat Mesenteric Resistance Arteries Arterioscler. Thromb. Vasc. Biol., August 1, 2001; 21(8): 1288 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Davis, X. Wu, T. R. Nurkiewicz, J. Kawasaki, G. E. Davis, M. A. Hill, and G. A. Meininger Integrins and mechanotransduction of the vascular myogenic response Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1427 - H1433. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |